Enhanced cellular immune response against SIV Gag induced by immunization with DNA vaccines expressing assembly and release-defective SIV Gag proteins

Virology

Volumn 309, Issue 2, 2003, Pages 272-281

  Bu, Zhigao ^a   Ye, Ling ^a   Compans, Richard W ^a   Yang, Chinglai ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assembly; Cellular immune response; DNA immunization; Gag; Immunogenicity; Protein degradation; Simian immunodeficiency virus (SIV)

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAG PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CHIMERA; CODON USAGE; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; MUTATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; SEQUENCE HOMOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS IMMUNITY; WILD TYPE;

SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0037565206     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00066-7     Document Type: Article

References (56)

1. Amara R.A., Villinger F., Altman J.D., Lydy S.L., O'nell S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
2. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72:1998;1497-1503.
3. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., Frost J.D., Krivulka G.R., Lifton M.A., Crabbs C.L., Heidecker G., Perry H.C., Davies M.E., Xie H., Nickerson C.E., Steenbeke T.D., Lord C.I., Montefiori D.C., Strom T.B., Shiver J.W., Lewis M.G., Letvin N.L. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA. 97:2000;4192-4197.
4. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., Fu T.M., Nam J.H., Wyatt L.S., Lifton M.A., Krivulka G.R., Nickerson C.E., Lord C.I., Moss B., Lewis M.G., Hirsch V.M., Shiver J.W., Letvin N.L. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 75:2001;2462-2467.
5. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
6. Belich M.P., Trowsdale J. Proteasome and class I antigen processing and presentation. Mol Biol Rep. 21:1995;53-56.
7. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
8. Brander C., Walker B.D. T lymphocyte responses in HIV-1 infection implications for vaccine development . Curr. Opin. Immunol. 11:1999;451-459.
9. Bryant M., Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA. 87:1990;523-527.
10. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection differential CTL responses to HIV-1 and Epstein-Barr virus in late disease . J. Exp. Med. 177:1993;249-256.
11. Chen Z.W., Kou Z.C., Lekutis C., Shen L., Zhou D., Halloran M., Li J., Sodroski J., Lee-Parritz D., Letvin N.L. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J. Exp. Med. 182:1995;21-31.
12. Ciurea A., Hunziker L., Klenerman P., Hengartner H., Zinkernagel R.M. Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193:2001;297-305.
13. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65:1996;801-847.
14. Curiel T.J., Wong J.T., Gorczyca P.F., Schooley R.T., Walker B.D. CD4+ human immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1-infected individual. AIDS Res. Hum. Retroviruses. 9:1993;61-68.
15. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., Wolf H., Wagner R. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75:2001;10991-11001.
16. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76:2002;2298-2305.
17. Franco A., Tilly D.A., Gramaglia I., Croft M., Cipolla L., Meldal M., Grey H.M. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat. Immunol. 1:2000;145-150.
18. Freed E.O. HIV-1 gag proteins diverse functions in the virus life cycle . Virology. 251:1998;1-15.
19. Goldberg A.L., Rock K. Proteosomes and antigen presentation. Nature. 357:1992;375-379.
20. Goulder P.J., Rowland-Jones S.L., McMichael A., Walker B.D. Anti-HIV cellular immunity recent advances towards vaccine design . AIDS. 13:(Suppl. A):1999;S121-S136.
21. Grant E.P., Michalek M.T., Goldberg A.L., Rock K.L. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155:1995;3750-3758.
22. Groettrup M., Soza A., Kuckelkom U., Kloetzel P.M. Peptide antigen production by the proteasome complexity provides efficiency . Immunol. Today. 17:1996;429-435.
23. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines immunology, application, and optimization . Annu. Rev. Immunol. 18:2000;927-974.
24. Haas J., Park E.C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:1996;315-324.
25. Harty J.T., Tvinnereim A.R., White D.W. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18:2000;275-308.
26. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Immunol. 67:1998;425-479.
27. Holtzman E. Lysosomes. 1989;Plenum Press, New York.
28. Kelly A., Powis S.H., Kerr L.A., Mockridge I., Elliott T., Bastin J., Uchanska-Ziegler B., Ziegler A., Trowsdale J., Townsend A. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature. 355:1992;641-644.
29. Klain M.R., van Baalen C.A., Holwerda A.M., Kerkhof Garde S.R., Bende R.J., Keet I.P., Eeftinck-Schattenkerk J.K., Osterhaus A.D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection a longitudinal analysis of rapid progressors and long-term asymptomatics . J. Exp. Med. 181:1995;1365-1372.
30. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
31. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186:1997;859-865.
32. Lawson T.G., Gronros D.L., Evans P.E., Bastien M.C., Michalewich K.M., Clark J.K., Edmonds J.H., Graber K.H., Werner J.A., Lurvey B.A., Cate J.M. Identification and characterization of a protein destruction signal in the encephalomyocarditis virus 3C protease. J. Biol. Chem. 274:1999;9904-9980.
33. Letvin N.L., Bloom B.R., Hoffman S.L. Prospects for vaccines to protect against AIDS, tuberculosis, and malaria. JAMA. 285:2001;606-611.
34. Mammano F., Ohagen A., Hoglund S., Gottlinger H.G. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68:1994;4927-4936.
35. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
36. zur Megede J., Chen M.C., Doe B., Schaefer M., Greer C.E., Selby M., Otten G.R., Barnett S.W. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74:2000;2628-2635.
37. Morikawa Y., Hinata S., Tomoda H., Goto T., Nakai M., Aizawa C., Tanaka H., Omura S. Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. J. Biol. Chem. 271:1996;2868-2873.
38. Nabel G.J. Challenges and opportunities for development of an AIDS vaccine. Nature. 410:2001;1002-1007.
39. Neefjes J.J., Momburg F., Hammerling G.J. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science. 261:1993;769-771.
40. Norris P.J., Sumaroka M., Brander C., Moffett H.F., Boswell S.L., Nguyen T., Sykulev Y., Walker B.D., Rosenberg E.S. Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J. Virol. 75:2001;9771-9779.
41. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
42. Pamer E., Cresswell P. Mechanisms of MHC class I - restricted antigen processing. Annu. Rev. Immunol. 16:1998;323-358.
43. Picker L.J. Proving HIV-1 immunity new tools offer new opportunities . J. Clin. Invest. 105:2000;1333-1334.
44. Planz O., Ehl S., Furrer E., Horvath E., Brundler M.A., Hengartner H., Zinkernagel R.M. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus implications for adoptive immunotherapy of virus carriers . Proc. Natl. Acad. Sci. USA. 94:1997;6874-6879.
45. Restifo N.P., Bacik I., Irvine K.R., Yewdell J.W., McCabe B.J., Anderson R.W., Eisenlohr L.C., Rosenberg S.A., Bennink J.R. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:1995;4414-4422.
46. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
47. Robinson H.L., Smith J.M., Amara R.R. AIDS vaccine heterologous prime/boost strategies for raising protective T cell response . AIDS Rev. 2:2000;105-110.
48. Rodriguez F., Zhang J., Whitton J.L. DNA immunization ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction . J. Virol. 71:1997;8497-8503.
49. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
50. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:1999;857-860.
51. Shiver J.W., Fu T.M., Chen L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
52. Tobery T.W., Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185:1997;909-920.
53. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., Boyle D., Chan S., Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168:1988;1211-1224.
54. Uchijima M., Yoshida A., Nagata T., Koide Y.J. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol. 161:1998;5594-5599.
55. Venturini S., Mosier D.E., Burton D.R., Poignard P. Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J. Virol. 76:2002;6987-6999.
56. Zajac A.J., Murali-Krishna K., Blattman J.N., Ahmed R. Therapeutic vaccination against chronic viral infection the importance of cooperation between CD4+ and CD8+ T cells . Curr. Opin. Immunol. 10:1998;444-449.